Akebia Therapeutics Inc (NASDAQ: AKBA) kicked off on Monday, down -5.02% from the previous trading day, before settling in for the closing price of $3.19. Over the past 52 weeks, AKBA has traded in a range of $1.24-$4.08.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 32.58% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 49.09%. With a float of $250.51 million, this company’s outstanding shares have now reached $263.04 million.
In an organization with 181 employees, it is important to assess its efficiency.
Akebia Therapeutics Inc (AKBA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Akebia Therapeutics Inc is 5.52%, while institutional ownership is 39.95%. The most recent insider transaction that took place on Jun 30 ’25, was worth 151,622. In this transaction SVP, CFO, CBO & Treasurer of this company sold 41,314 shares at a rate of $3.67, taking the stock ownership to the 503,586 shares. Before that another transaction happened on Jun 30 ’25, when Company’s Officer proposed sale 41,314 for $3.67, making the entire transaction worth $151,622.
Akebia Therapeutics Inc (AKBA) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.1 earnings per share (EPS), lower than consensus estimate (set at -0.05) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 49.09% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Take a look at Akebia Therapeutics Inc’s (AKBA) current performance indicators. Last quarter, stock had a quick ratio of 1.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.17, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.08 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Let’s dig in a bit further. During the last 5-days, its volume was 3.35 million. That was inferior than the volume of 4.15 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 29.34%.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 59.01%, which indicates a significant increase from 12.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.16 in the past 14 days, which was lower than the 0.17 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.59, while its 200-day Moving Average is $2.54. However, in the short run, Akebia Therapeutics Inc’s stock first resistance to watch stands at $3.15. Second resistance stands at $3.28. The third major resistance level sits at $3.34. If the price goes on to break the first support level at $2.96, it is likely to go to the next support level at $2.90. Assuming the price breaks the second support level, the third support level stands at $2.77.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
The company with the Market Capitalisation of 803.37 million has total of 265,145K Shares Outstanding. Its annual sales at the moment are 160,180 K in contrast with the sum of -69,410 K annual income. Company’s last quarter sales were recorded 62,470 K and last quarter income was 250 K.
